neoplasms normalizes inflammatory cytokines in murine myeloproliferative CYT387, a novel JAK2 inhibitor, induces hematologic responses and

[1]  J. Cortes,et al.  A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis , 2008 .

[2]  H. Kantarjian,et al.  A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) , 2008 .

[3]  Sandra A. Moore,et al.  Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.

[4]  G. Noronha,et al.  Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. , 2008, Cancer cell.

[5]  B. Druker,et al.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. , 2008, Blood.

[6]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[7]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[8]  Chunaram Choudhary,et al.  Activation mechanisms of STAT5 by oncogenic Flt3-ITD. , 2006, Blood.

[9]  B. Druker,et al.  Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.

[10]  B. Druker,et al.  Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. , 2006, Blood.

[11]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[12]  H. Kantarjian,et al.  Janus kinase 2: a critical target in chronic myelogenous leukemia. , 2006, Cancer research.

[13]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[14]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[15]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[16]  M. Loh,et al.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.

[17]  E. Hatzimichael,et al.  Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases , 2005, British journal of haematology.

[18]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[19]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[20]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[21]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[22]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[23]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[24]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[25]  P. Dent,et al.  Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. , 2003, Blood.

[26]  E. Wong,et al.  Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes , 2002, Gene Therapy.

[27]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[28]  L. Moldawer,et al.  Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.